TOP TEN perturbations for 1553352_x_at (Homo sapiens)

Organism: Homo sapiens
Gene: 1553352_x_at
Selected probe(set): 1553352_x_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of 1553352_x_at (1553352_x_at) across 6672 perturbations tested by GENEVESTIGATOR:

hypoxia study 11 (HK2) / control HK2 cell sample (normoxia)

Relative Expression (log2-ratio):2.0178041
Number of Samples:3 / 6
Experimental hypoxia study 11 (HK2)
Proximal tubule epithelial cell line HK-2 treated with hypoxia (1% O2) for 24 hours. HK-2 cells were cultured in DMEM/F-12 supplemented with 10% fetal calf serum (FCS), 1% ITS, hydrocortisone, and antibiotics. The cells were incubated at 37 °C.
Control control HK2 cell sample (normoxia)
Proximal tubule epithelial cell line HK-2 treated with normoxia (20% O2) for 24 hours. HK-2 cells were cultured in DMEM/F-12 supplemented with 10% fetal calf serum (FCS), 1% ITS, hydrocortisone, and antibiotics. The cells were incubated at 37 °C.

expO ovary cancer study 1 (dysgerminoma; metastatic) / expO ovary cancer study 1 (carcinoma, NOS; metastatic)

Relative Expression (log2-ratio):1.9592209
Number of Samples:2 / 5
Experimental expO ovary cancer study 1 (dysgerminoma; metastatic)
Metastatic tumor tissue samples obtained from patients with primary dysgerminoma of the ovary.
Control expO ovary cancer study 1 (carcinoma, NOS; metastatic)
Metastatic tumor tissue samples obtained from patients with primary carcinoma (NOS) of the ovary.

expO ovary cancer study 1 (papillary serous cystadenocarcinoma; metastatic) / expO ovary cancer study 1 (dysgerminoma; metastatic)

Relative Expression (log2-ratio):-1.7758207
Number of Samples:51 / 2
Experimental expO ovary cancer study 1 (papillary serous cystadenocarcinoma; metastatic)
Metastatic tumor tissue samples obtained from patients with primary papillary serous cystadenocarcinoma of the ovary.
Control expO ovary cancer study 1 (dysgerminoma; metastatic)
Metastatic tumor tissue samples obtained from patients with primary dysgerminoma of the ovary.

cadmium study 1 (brief) / untreated NPrEC cell sample

Relative Expression (log2-ratio):1.7588196
Number of Samples:2 / 2
Experimental cadmium study 1 (brief)
After 72h of starvation, NPrEC cells were briefly exposed to 2.5 uM CdCl2. ATC code:---
Control untreated NPrEC cell sample
After 72h of starvation, NPrEC cells were briefly exposed to complete medium without CdCl2.

expO ovary cancer study 1 (endometrioid carcinoma; metastatic) / expO ovary cancer study 1 (dysgerminoma; metastatic)

Relative Expression (log2-ratio):-1.7498217
Number of Samples:3 / 2
Experimental expO ovary cancer study 1 (endometrioid carcinoma; metastatic)
Metastatic tumor tissue samples obtained from patients with primary endometrioid carcinoma of the ovary.
Control expO ovary cancer study 1 (dysgerminoma; metastatic)
Metastatic tumor tissue samples obtained from patients with primary dysgerminoma of the ovary.

expO ovary cancer study 1 (mucinous adenocarcinoma; metastatic) / expO ovary cancer study 1 (dysgerminoma; metastatic)

Relative Expression (log2-ratio):-1.7136221
Number of Samples:2 / 2
Experimental expO ovary cancer study 1 (mucinous adenocarcinoma; metastatic)
Metastatic tumor tissue samples obtained from patients with primary mucinous adenocarcinoma of the ovary.
Control expO ovary cancer study 1 (dysgerminoma; metastatic)
Metastatic tumor tissue samples obtained from patients with primary dysgerminoma of the ovary.

expO ovary cancer study 1 (serous surface papillary carcinoma; metastatic) / expO ovary cancer study 1 (dysgerminoma; metastatic)

Relative Expression (log2-ratio):-1.6986752
Number of Samples:2 / 2
Experimental expO ovary cancer study 1 (serous surface papillary carcinoma; metastatic)
Metastatic tumor tissue samples obtained from patients with primary serous surface papillary carcinoma of the ovary.
Control expO ovary cancer study 1 (dysgerminoma; metastatic)
Metastatic tumor tissue samples obtained from patients with primary dysgerminoma of the ovary.

expO ovary cancer study 1 (dysgerminoma; metastatic) / expO ovary cancer study 1 (adenocarcinoma, NOS; metastatic)

Relative Expression (log2-ratio):1.6794825
Number of Samples:2 / 7
Experimental expO ovary cancer study 1 (dysgerminoma; metastatic)
Metastatic tumor tissue samples obtained from patients with primary dysgerminoma of the ovary.
Control expO ovary cancer study 1 (adenocarcinoma, NOS; metastatic)
Metastatic tumor tissue samples obtained from patients with primary adenocarcinoma (NOS) of the ovary.

expO ovary cancer study 1 (serous cystadenocarcinoma, NOS; metastatic) / expO ovary cancer study 1 (dysgerminoma; metastatic)

Relative Expression (log2-ratio):-1.6719885
Number of Samples:8 / 2
Experimental expO ovary cancer study 1 (serous cystadenocarcinoma, NOS; metastatic)
Metastatic tumor tissue samples obtained from patients with primary serous cystadenocarcinoma (NOS) of the ovary.
Control expO ovary cancer study 1 (dysgerminoma; metastatic)
Metastatic tumor tissue samples obtained from patients with primary dysgerminoma of the ovary.

expO ovary cancer study 1 (dysgerminoma; metastatic) / expO ovary cancer study 1 (clear cell adenocarcinoma, NOS; metastatic)

Relative Expression (log2-ratio):1.6248856
Number of Samples:2 / 4
Experimental expO ovary cancer study 1 (dysgerminoma; metastatic)
Metastatic tumor tissue samples obtained from patients with primary dysgerminoma of the ovary.
Control expO ovary cancer study 1 (clear cell adenocarcinoma, NOS; metastatic)
Metastatic tumor tissue samples obtained from patients with primary clear cell adenocarcinoma (NOS) of the ovary.